系统文献综述:为关于生物改善病情抗风湿药选择性抑制白细胞介素-6通路治疗免疫介导炎症性疾病的疗效与安全性的共识声明提供依据
该系统文献综述检索了2012年1月至2020年12月间MEDLINE、EMBASE和Cochrane CENTRAL数据库中关于生物改善病情抗风湿药选择性抑制IL-6通路的出版物,共纳入187篇文章。结果显示IL-6抑制对类风湿关节炎、幼年特发性关节炎、巨细胞动脉炎、大动脉炎、成人起病Still病、CAR-T所致细胞因子释放综合征及系统性硬化症相关间质性肺病等有积极疗效,但对银屑病关节炎、强直性脊柱炎及某些结缔组织病无效;安全性与其他bDMARDs广泛可比,但憩室炎和下消化道穿孔风险较高,比较TCZ与TNF抑制剂感染风险的研究结果不一致。
要点
- IL-6抑制对类风湿关节炎、幼年特发性关节炎、巨细胞动脉炎、大动脉炎、成人起病Still病、CAR-T所致细胞因子释放综合征及系统性硬化症相关间质性肺病有积极疗效证据。
- IL-6抑制对银屑病关节炎、强直性脊柱炎及某些结缔组织病未提供治疗获益。
- 安全性与其他bDMARDs广泛可比,但憩室炎和下消化道穿孔风险较高;比较TCZ与TNF抑制剂感染风险的研究结果不一致。
核心结论
- IL-6抑制对多种炎症性疾病的治疗有效,其安全性与其他bDMARDs广泛可比。
研究设计与样本
- 系统文献检索MEDLINE、EMBASE和Cochrane CENTRAL数据库中2012年1月至2020年12月发表的关于bDMARDs抑制IL-6轴的所有出版物,并考虑ACR、EULAR会议摘要及clinicaltrials.gov结果。
- 共187篇文章符合纳入标准,评估临床试验(含长期扩展)和观察性研究中的疗效与安全性结局。
主要发现
- IL-6抑制在类风湿关节炎、幼年特发性关节炎、巨细胞动脉炎、大动脉炎、成人起病Still病、CAR-T所致细胞因子释放综合征及系统性硬化症相关间质性肺病等多种炎症性疾病中具有积极疗效证据。
- 萨特利珠单抗和抗IL-6配体抗体司妥昔单抗分别扩展了Castleman病和视神经脊髓炎的治疗途径。
- IL-6抑制对银屑病关节炎、强直性脊柱炎及某些结缔组织病未提供治疗获益。
- 在COVID-19中,托珠单抗(TCZ)已被证明对晚期疾病有治疗作用。
- 安全性结局与其他bDMARDs无差异,但憩室炎和下消化道穿孔风险较高;比较TCZ与TNF抑制剂感染风险的若干研究结果不一致。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Informing an international task force updating the consensus statement on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) selectively targeting interleukin-6 (IL-6) pathway in the context of immune-mediated inflammatory diseases. METHODS: A systematic literature research of all publications on IL-6 axis inhibition with bDMARDs published between January 2012 and December 2020 was performed using MEDLINE, EMBASE and Cochrane CENTRAL databases. Efficacy and safety outcomes were assessed in clinical trials including their long-term extensions and observational studies. Meeting abstracts from ACR, EULAR conferences and results on clinicaltrials.gov were taken into consideration. RESULTS: 187 articles fulfilled the inclusion criteria. Evidence for positive effect of IL-6 inhibition was available in various inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, cytokine release syndrome due to chimeric antigen receptor T cell therapy and systemic sclerosis-associated interstitial lung disease. Newcomers like satralizumab and anti-IL-6 ligand antibody siltuximab have expanded therapeutic approaches for Castleman's disease and neuromyelitis optica, respectively. IL-6 inhibition did not provide therapeutic benefits in psoriatic arthritis, ankylosing spondylitis and certain connective tissue diseases. In COVID-19, tocilizumab (TCZ) has proven to be therapeutic in advanced disease. Safety outcomes did not differ from other bDMARDs, except higher risks of diverticulitis and lower gastrointestinal perforations. Inconsistent results were observed in several studies investigating the risk for infections when comparing TCZ to TNF-inhibitors. CONCLUSION: IL-6 inhibition is effective for treatment of several inflammatory diseases with a safety profile that is widely comparable to other bDMARDs.
引用
- Kastrati K, Aletaha D, Burmester GR, et al. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open. 2022. PMID: 36260501. doi:10.1136/rmdopen-2022-002359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。